On April 29, 2021 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer reported the acceptance of two poster presentations for DANYELZA and an oral presentation for omburtamab at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") Virtual Annual Meeting, taking place virtually from June 4, 2021 to June 8, 2021 (Press release, Y-mAbs Therapeutics, APR 29, 2021, View Source,-April%2029%2C%202021&text=Researchers%20at%20MSK%20developed%20DANYELZA,financial%20interests%20in%20the%20products. [SID1234578830]). The presentations were submitted by Dr. Brian Kushner, Memorial Sloan Kettering Cancer Center ("MSK"), Dr. Jaume Mora, M.D., Ph.D., SJD Barcelona Children’s Hospital and Dr. Mark Souweidane, MSK and Weill Cornell Medicine:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DANYELZA (naxitamab-gqgk)
Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease (Dr. Kushner)
Naxitamab and GM-CSF for consolidation of High-Risk neuroblastoma (HR-NB) patients in complete remission (Dr. Mora)
Omburtamab
Phase 1 dose-escalation trial using convection-enhanced delivery of 124I-omburtamab for diffuse intrinsic pontine glioma following external radiation therapy (Dr. Souweidane)
Researchers at MSK developed DANYELZA and omburtamab, which are exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the products.